Project Grant R01HL171977
Award Date
8/15/24
Completion Date
7/31/27
Dollars Obligated
$693K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New Brunswick, NJ 08901, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor self-renewal, both in vitro and in vivo. The $677,600 award to the University of Rochester supports research to examine how the BMI1/RING1B chromatin regulatory complex modulates the self-renewal capacity of human erythroblasts through epigenetic control of transcription and cholesterol homeostasis. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $131,250 to the Vitalant Research Institute (VRI) to investigate the potential transmission of cerebral amyloid angiopathy (CAA) through blood transfusions. The primary objectives are to (A) examine the prevalence of amyloid-beta pathology among blood donors, and (B) determine if amyloid-beta can be transmitted from affected...
The federal Project Grant award of $344,304 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a learning health system approach to improve the effectiveness of blood transfusions during septic shock. The project aims to address the high incidence of anemia and associated morbidity and mortality in patients with septic shock, a common and often fatal condition resulting from a dysregulated host response to...
The federal Project Grant award F31HL172674, with a total funding amount of $207,910.00, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the metabolic regulation of erythropoiesis, or the development of red blood cells. Specifically, the research aims to determine the role of the malate-aspartate shuttle, a mechanism that transfers electrons into the mitochondria,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), aims to engineer hemostatic red blood cells that can adhere to collagen and fibrin at injury sites to help stop non-compressible hemorrhage. The $234,000 award to the University of Colorado-Denver will fund research to: 1) synthesize the engineered red blood cells, 2) test their ability to enhance clot formation and stability in...
This $792,498 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Indiana University Indianapolis to investigate the role of oxygen levels in regulating the function and regenerative capacity of hematopoietic stem cells (HSCs). The research aims to elucidate the signaling and metabolic pathways by which hypoxic conditions in the bone marrow promote HSC self-renewal and prevent...
The federal Project Grant award R01HL175339, valued at $596,401.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research to investigate the role of a novel long non-coding RNA named MCRL1 in regulating human cardiac and hematopoietic differentiation during the mesoderm specification stage of embryogenesis. The research aims to decipher the transcriptional and epigenetic mechanisms by...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 project grant to Case Western Reserve University. The 4-year grant, effective September 1, 2024, supports the development and validation of a novel "transfer volume regression" model to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $392,660 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania to investigate the role of red blood cells (RBCs) in regulating the immune response during sepsis. The project aims to establish the subcellular localization of the Toll-like receptor 7 (TLR7) in human RBCs, determine RBC-TLR7's RNA-sequestration capabilities during sepsis, and define the erythroid-specific...
This federal Project Grant award of $616,914.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a research project at Harvard Medical School investigating the mechanisms by which the ubiquitin-proteasome system, specifically the UBE2O enzyme, mediates protein quality control and ribosome homeostasis during red blood cell...